Dimerix jumps on China nod for recruitment for kidney disease drug study

Dimerix

28/11/2023 03:52

** Shares of Australia's Dimerix  DXB.AX  rise as much as
17.9% to A$0.165, their biggest intraday pct gain since Oct. 11
    ** Stock at its highest level since Nov. 15
    ** Biopharmaceutical co says Investigational New Drug (IND)
recruitment application for DMX-200 approved by National Medical
Products Administration (NMPA), the Chinese regulatory agency
    ** Says NMPA approved IND application to begin recruitment
of patients for ACTION3 Phase 3 study of DMX-200   
    ** DMX-200 drug for focal segmental glomerulosclerosis
(FSGS) kidney disease - DXB
    ** Stock down 1.7% YTD, as of last close

 (Reporting by Roshan Thomas in Bengaluru)
 ((Roshan.Thomas@thomsonreuters.com;))